KRAS and cancer: An analysis of 96 mutations in nine cancer driver genes (BRAF, CTNNB1, EGFR, FOXL2, GNAS, KRAS, NRAS, PIK3CA, and TP53) detected mutations in plasma cfDNA in 6% (12/200) of individuals undergoing colonoscopy; 42% of these individuals had polyps, and the rest had negative finding on colonoscopy [114].